enVVeno Medical CEO presents at Virtual Investor “Why Now” on-demand conference
NVNO•CEO presentation at Virtual Investor conference
enVVeno Medical CEO Robert Berman participated in Virtual Investor’s “Why Now” on-demand conference.
- Presentation highlighted FDA IDE clearance for a U.S. pivotal study of enVVe, a non-surgical replacement venous valve for severe DVI.
- TAVVE pivotal trial expected to start in Q4 2026, targeting about 230 patients across up to 40 U.S. sites.
